AVORO CAPITAL ADVISORS LLC
Q2 2026 Form 13-F
NEW YORK, NEW YORK
CIK 0001633313
· CRD 154091
· SEC-registered investment adviser
$11.1B Reported Value Total
AVORO CAPITAL ADVISORS LLC reports 3 total accounts under management (AUM). There are 3 discretionary accounts valued at $13,550,212,784, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
4 funds
· $14.0B gross asset value
Hedge Fund: $13.4B · Venture Capital Fund: $647.5M
Source: Form ADV filed 2026-03-05
Reported value
$11.1B
Quarter over quarter
+20.8%
Holdings
26
Top-10 concentration
79.5%
Key People
Form ADV owners & control persons
Behzad Aghazadeh
MEMBER
Neil Cammarosano
CHIEF FINANCIAL OFFICER
Scott Andrew Epstein
CHIEF OPERATING OFFICER AND CHIEF COMPLIANCE OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q2 2026 13F record
Q2 2026 13F filing summary
| Period of report | June 30, 2026 |
|---|---|
| Filed | August 14, 2026 |
| Form | 13F-HR |
| Reported value | $11.1B |
| Positions | 26 |
| Change in reported value | +9.6% |
| New positions | 3 |
| Exited positions | 7 |
| Position turnover | 30.3% |
| Top-10 concentration | 79.5% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
26 | $11.1B |
|
Q1 2026 13F
Filed May 15, 2026
|
30 | $10.2B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
33 | $10.2B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
30 | $7.7B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
30 | $5.7B |
|
Q1 2025 13F
Filed May 15, 2025
|
33 | $6.4B |
|
Q4 2024 13F
Filed Feb 14, 2025
|
39 | $7.1B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
35 | $6.9B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
41 | $7.5B |
|
Q1 2024 13F
Filed May 15, 2024
|
46 | $8.6B |
|
Q4 2023 13F
Filed Feb 14, 2024
|
42 | $7.2B |
|
Q3 2023 13F
Filed Nov 14, 2023
|
45 | $6.4B |
|
Q2 2023 13F
Filed Aug 14, 2023
|
43 | $7.4B |
|
Q1 2023 13F
Filed May 15, 2023
|
38 | $6.7B |
|
Q4 2022 13F
Filed Feb 14, 2023
|
36 | $6.7B |
|
Q3 2022 13F
Filed Nov 14, 2022
|
39 | $5.4B |
|
Q2 2022 13F
Filed Aug 15, 2022
|
40 | $5.1B |
|
Q1 2022 13F
Filed May 16, 2022
|
43 | $5.5B |
|
Q4 2021 13F
Filed Feb 14, 2022
|
40 | $5.9B |
|
Q3 2021 13F
Filed Nov 15, 2021
|
43 | $6.4B |
27 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q2 2026
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | UTHR UNITED THERAPEUTICS CORP | $1.5B | 13.52% |
| 2 | ASND ASCENDIS PHARMA | $1.4B | 12.24% |
| 3 | KRYS KRYSTAL BIOTECH INC | $1.1B | 9.64% |
| 4 | MDGL MADRIGAL PHARMACEUTICALS INC | $984.4M | 8.84% |
| 5 | ARGX ARGENX SE | $927.8M | 8.33% |
| 6 | ARWR ARROWHEAD PHARMACEUTICALS INC | $925.6M | 8.31% |
| 7 | KYMR KYMERA THERAPEUTICS INC | $857.1M | 7.7% |
| 8 | RVMD REVOLUTION MEDICINES INC | $430.2M | 3.86% |
| 9 | CYTK CYTOKINETICS INC | $425.9M | 3.82% |
| 10 | CELC CELCUITY INC | $355.7M | 3.19% |
| 11 | GPCR STRUCTURE THERAPEUTICS INC | $351.8M | 3.16% |
| 12 | XENE XENON PHARMACEUTICALS INC | $348.7M | 3.13% |
| 13 | DFTX DEFINIUM THERAPEUTICS INC | $338.2M | 3.04% |
| 14 | QURE UNIQURE NV | $309.9M | 2.78% |
| 15 | VERA VERA THERAPEUTICS INC | $245.6M | 2.21% |
| 16 | TSHA TAYSHA GENE THERAPIES INC | $162.7M | 1.46% |
| 17 | OCUL OCULAR THERAPEUTIX INC | $123.1M | 1.11% |
| 18 | GLTO DAMORA THERAPEUTICS INC | $98.4M | 0.88% |
| 19 | COAG HEMAB THERAPEUTICS HLDGS INC | $70.7M | 0.63% |
| 20 | GHRS GH RESEARCH PLC | $48.4M | 0.43% |
Values as reported on the Q2 2026 Form 13F. Every position is in the holdings table below.